Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bumetanide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | CISD1 | Q9NZ45 | 9/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA6 | P23280 | 2/20 | 0.64 |
| ▸ | CA5A | P35218 | 2/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.64 |
| ▸ | CA9 | Q16790 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11788072 | 0.84 | ALDH1A1 (0.64) | CA2ALDH1A1KDM4EUSP2LMNA | |
| SCHEMBL19300067 | 0.83 | ALDH1A1 (0.61) | CA2ALDH1A1KDM4EUSP2LMNA | |
| Bumetanide SCHEMBL27525 | 0.82 | KDM4E (1.00) | CA2ALDH1A1KDM4EUSP2LMNA | |
| Bumetanide SCHEMBL29388271 | 0.82 | KDM4E (1.00) | CA2ALDH1A1KDM4EUSP2LMNA | |
| Bumetanide SCHEMBL4425232 | 0.82 | KDM4E (1.00) | CA2ALDH1A1KDM4EUSP2LMNA | |
| Bumetanide SCHEMBL23455698 | 0.81 | KDM4E (0.98) | CA2ALDH1A1KDM4EUSP2LMNA | |
| Bumetanide SCHEMBL2255359 | 0.81 | KDM4E (0.98) | CA2ALDH1A1KDM4EUSP2LMNA | |
| Bumetanide SCHEMBL6239781 | 0.81 | KDM4E (0.98) | CA2ALDH1A1KDM4EUSP2LMNA | |
| Bumetanide SCHEMBL251062 | 0.81 | KDM4E (0.98) | CA2ALDH1A1KDM4EUSP2LMNA | |
| Bumetanide SCHEMBL28661289 | 0.81 | KDM4E (0.98) | CA2ALDH1A1KDM4EUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103717597-B | Heterocyclic compounds as kinase inhibitors | 原真股份有限公司 | 2017-07-04 | — | — | CN | disclosed |
| CN-103492389-B | Pyrazolo [4,3-d] pyrimidine as inhibitors of kinases | 原真股份有限公司 | 2016-09-14 | — | — | CN | disclosed |
| EP-1414845-A4 | HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1404702-A4 | HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES INC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-1379132-A4 | HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1951702-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-02-17 | — | — | US | disclosed |
| EP-1460062-A1 | NITROGENOUS CYCLIC KETONE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| EP-1414845-A2 | HUMAN SECRETED PROTEINS | Human Genome Sciences (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1404702-A2 | HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1385381-A2 | HUMAN SECRETED PROTEINS | Human Genome Sciences, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379132-A2 | HUMAN SECRETED PROTEINS | Human Genome Sciences (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003004623-A2 | HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003004622-A2 | HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003000865-A2 | HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002102994-A2 | HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002095010-A2 | HUMAN SECRETED PROTEINS | HUMAN GENOME SCIENCES, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038072-A1 | Nitrogeneous cyclic ketone derivative, process for producing the same, and use | BDKRB1, BDKRB2, TACR1 | CA2 1578/4885ALDH1A1 1984/4885KDM4E 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.